FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293298579> ?p ?o ?g. }

• W4293298579 abstract "Abstract Background Solid tumors subjected to intermittent hypoxia are characterized by resistance to chemotherapy and immune-killing by effector T-lymphocytes, particularly tumor-infiltrating Vγ9Vδ2 T-lymphocytes. The molecular circuitries determining this double resistance are not known. Methods We analyzed a panel of 28 human non-small cell lung cancer (NSCLC) lines, using an in vitro system simulating continuous and intermittent hypoxia. Chemosensitivity to cisplatin and docetaxel was evaluated by chemiluminescence, ex vivo Vγ9Vδ2 T-lymphocyte expansion and immune-killing by flow cytometry. Targeted transcriptomics identified efflux transporters and nuclear factors involved in this chemo-immuno-resistance. The molecular mechanism linking Hypoxia-inducible factor-1α (HIF-1α), CCAAT/Enhancer Binding Protein-β (C/EBP-β) isoforms LAP and LIP, ABCB1, ABCC1 and ABCA1 transporters were evaluated by immunoblotting, RT-PCR, RNA-IP, ChIP. Oxidative phosphorylation, mitochondrial ATP, ROS, depolarization, O 2 consumption were monitored by spectrophotometer and electronic sensors. The role of ROS/HIF-1α/LAP axis was validated in knocked-out or overexpressing cells, and in humanized (Hu-CD34 + NSG) mice bearing LAP-overexpressing tumors. The clinical meaning of LAP was assessed in 60 NSCLC patients prospectively enrolled, treated with chemotherapy. Results By up-regulating ABCB1 and ABCC1, and down-regulating ABCA1, intermittent hypoxia induced a stronger chemo-immuno-resistance than continuous hypoxia in NSCLC cells. Intermittent hypoxia impaired the electron transport chain and reduced O 2 consumption, increasing mitochondrial ROS that favor the stabilization of C/EBP-β mRNA mediated by HIF-1α. HIF-1α/C/EBP-β mRNA binding increases the splicing of C/EBP-β toward the production of LAP isoform that transcriptionally induces ABCB1 and ABCC1, promoting the efflux of cisplatin and docetaxel. LAP also decreases ABCA1, limiting the efflux of isopentenyl pyrophosphate, i.e. the endogenous activator of Vγ9Vδ2 T-cells, and reducing the immune-killing. In NSCLC patients subjected to cisplatin-based chemotherapy, C/EBP-β LAP was abundant in hypoxic tumors and was associated with lower response to treatment and survival. LAP-overexpressing tumors in Hu-CD34 + NSG mice recapitulated the patients’ chemo-immuno-resistant phenotype. Interestingly, the ROS scavenger mitoquinol chemo-immuno-sensitized immuno-xenografts, by disrupting the ROS/HIF-1α/LAP cascade. Conclusions The impairment of mitochondrial metabolism induced by intermittent hypoxia increases the ROS-dependent stabilization of HIF-1α/LAP complex in NSCLC, producing chemo-immuno-resistance. Clinically used mitochondrial ROS scavengers may counteract such double resistance. Moreover, we suggest C/EBP-β LAP as a new predictive and prognostic factor in NSCLC patients." @default.
• W4293298579 created "2022-08-27" @default.
• W4293298579 creator A5004647809 @default.
• W4293298579 creator A5006463761 @default.
• W4293298579 creator A5012622459 @default.
• W4293298579 creator A5028628967 @default.
• W4293298579 creator A5038060413 @default.
• W4293298579 creator A5040632094 @default.
• W4293298579 creator A5053596264 @default.
• W4293298579 creator A5060939642 @default.
• W4293298579 creator A5062440907 @default.
• W4293298579 creator A5066967591 @default.
• W4293298579 creator A5076449178 @default.
• W4293298579 creator A5089375290 @default.
• W4293298579 creator A5090805323 @default.
• W4293298579 date "2022-08-11" @default.
• W4293298579 modified "2023-10-15" @default.
• W4293298579 title "Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer" @default.
• W4293298579 cites W1107917109 @default.
• W4293298579 cites W1809795104 @default.
• W4293298579 cites W1886778934 @default.
• W4293298579 cites W1968520204 @default.
• W4293298579 cites W1985458442 @default.
• W4293298579 cites W2006434892 @default.
• W4293298579 cites W2014929526 @default.
• W4293298579 cites W2017575850 @default.
• W4293298579 cites W2024811210 @default.
• W4293298579 cites W2025253425 @default.
• W4293298579 cites W2060179384 @default.
• W4293298579 cites W2094518946 @default.
• W4293298579 cites W2094929127 @default.
• W4293298579 cites W2106417441 @default.
• W4293298579 cites W2116102471 @default.
• W4293298579 cites W2116531861 @default.
• W4293298579 cites W2183777144 @default.
• W4293298579 cites W2334695248 @default.
• W4293298579 cites W2407477249 @default.
• W4293298579 cites W2526211783 @default.
• W4293298579 cites W2589091658 @default.
• W4293298579 cites W2623744214 @default.
• W4293298579 cites W2792183882 @default.
• W4293298579 cites W2902481242 @default.
• W4293298579 cites W2911577345 @default.
• W4293298579 cites W2964095295 @default.
• W4293298579 cites W2964471257 @default.
• W4293298579 cites W2969426297 @default.
• W4293298579 cites W2980701091 @default.
• W4293298579 cites W2982182315 @default.
• W4293298579 cites W2984799663 @default.
• W4293298579 cites W2991718894 @default.
• W4293298579 cites W3004829848 @default.
• W4293298579 cites W3009480075 @default.
• W4293298579 cites W3084111872 @default.
• W4293298579 cites W3092631461 @default.
• W4293298579 cites W3094061833 @default.
• W4293298579 cites W3109893680 @default.
• W4293298579 cites W3116841253 @default.
• W4293298579 cites W3117434538 @default.
• W4293298579 cites W3118142962 @default.
• W4293298579 cites W3118736194 @default.
• W4293298579 cites W3120756533 @default.
• W4293298579 cites W3127057353 @default.
• W4293298579 cites W3128687890 @default.
• W4293298579 cites W3177138808 @default.
• W4293298579 cites W3179416847 @default.
• W4293298579 cites W3194385700 @default.
• W4293298579 cites W3212101280 @default.
• W4293298579 cites W3217375757 @default.
• W4293298579 cites W4211032970 @default.
• W4293298579 cites W4221112451 @default.
• W4293298579 doi "https://doi.org/10.1186/s13046-022-02447-6" @default.
• W4293298579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35953814" @default.
• W4293298579 hasPublicationYear "2022" @default.
• W4293298579 type Work @default.
• W4293298579 citedByCount "10" @default.
• W4293298579 countsByYear W42932985792022 @default.
• W4293298579 countsByYear W42932985792023 @default.
• W4293298579 crossrefType "journal-article" @default.
• W4293298579 hasAuthorship W4293298579A5004647809 @default.
• W4293298579 hasAuthorship W4293298579A5006463761 @default.
• W4293298579 hasAuthorship W4293298579A5012622459 @default.
• W4293298579 hasAuthorship W4293298579A5028628967 @default.
• W4293298579 hasAuthorship W4293298579A5038060413 @default.
• W4293298579 hasAuthorship W4293298579A5040632094 @default.
• W4293298579 hasAuthorship W4293298579A5053596264 @default.
• W4293298579 hasAuthorship W4293298579A5060939642 @default.
• W4293298579 hasAuthorship W4293298579A5062440907 @default.
• W4293298579 hasAuthorship W4293298579A5066967591 @default.
• W4293298579 hasAuthorship W4293298579A5076449178 @default.
• W4293298579 hasAuthorship W4293298579A5089375290 @default.
• W4293298579 hasAuthorship W4293298579A5090805323 @default.
• W4293298579 hasBestOaLocation W42932985791 @default.
• W4293298579 hasConcept C104317684 @default.
• W4293298579 hasConcept C149011108 @default.
• W4293298579 hasConcept C153911025 @default.
• W4293298579 hasConcept C190283241 @default.
• W4293298579 hasConcept C203014093 @default.
• W4293298579 hasConcept C44312359 @default.
• W4293298579 hasConcept C502942594 @default.
• W4293298579 hasConcept C55493867 @default.

• next